Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.
Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC
Mainstreaming of Genetic Testing Is Tied to Increased Testing Rates in Ovarian Cancer
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC